Yuhan

Yuhan EBIT per Employee

The EBIT per Employee of Yuhan (000100.KS) as of Nov 2, 2026 is 144.23 M KRW. In the previous year, EBIT per Employee was 42.40 M KRW — a change of 240.20% (higher).

EBIT per Employee

144.23 MKRW

YoY

240.20%

Last updated:

EBIT per Employee of Yuhan is 2025 144.23 M KRW. EBIT per Employee of Yuhan was 2024 42.40 M KRW. It decreases by 240.20% higher compared to the previous year.

The Yuhan EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
31.45 M KRW
Jan 1, 2019
7.86 M KRW
Jan 1, 2020
52.86 M KRW
Jan 1, 2021
30.49 M KRW
Jan 1, 2022
22.60 M KRW
Jan 1, 2023
35.78 M KRW
Jan 1, 2024
42.40 M KRW
Jan 1, 2025
144.23 M KRW
The Yuhan EBIT per Employee history
YEAREBIT per EmployeeYoY
144.23 MKRW+240.20%
42.40 MKRW+18.49%
35.78 MKRW+58.30%
22.60 MKRW-25.86%
30.49 MKRW-42.32%
52.86 MKRW+572.12%
7.86 MKRW-74.99%
31.45 MKRW-43.49%
55.65 MKRW-9.29%
61.35 MKRW+13.93%
53.85 MKRW+15.38%
46.67 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yuhan Stock analysis

What does Yuhan do? The Yuhan Corporation is a South Korean conglomerate that was founded on September 1, 1926, under the name "Chosun Pharmaceutical Company". The company is headquartered in Seoul and employs more than 5,000 people worldwide. History: The Yuhan Corporation started as a small company with a single product, a fish oil-based ointment called "Yuksundo". The company worked hard to improve its products and expand its market, eventually expanding into other business areas such as the production of antibiotics and diabetes treatments. In the early 1950s, the company also ventured into the research and development of other pharmaceuticals. In 1962, Yuhan became a publicly traded company and received a variety of awards in the following years, including several Korean Industrial Awards. Since its inception, the company has remained committed to improving people's lives through innovation and science. Business model: The Yuhan Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of drugs and other health products. The company also makes investments in innovative technologies and healthcare startups. Over the years, Yuhan has expanded its business through partnerships with other companies and acquisitions of companies such as LGL Holdings and SillaJen Inc. The company also engages in international business relations, such as selling its products and medications in other countries. Divisions: The Yuhan Corporation has four main business divisions: Medical Research and Development, Drug Manufacturing, Biotechnology Product Development, and Health Product Production. The first division is coordinated by Yuhan Research & Development Co. Ltd, while drug manufacturing is done by Yuhan Manufacturing Co. Ltd. Biotechnology is done by Yuhan Biomedical Research Institute, and the health product segment is handled by Yuhan Healthcare. Products: Yuhan's products are diverse and include a wide range of drugs and health products. The company is involved in the production of antibiotics, analgesics, vein treatment agents, diabetes medications, cardiovascular drugs, and other pharmaceutical products. Other products also include cosmetics, oral care products, and dermatology drugs. Some of Yuhan's well-known products include the antibiotic Ceclor, a medication for the treatment of diabetes and metabolic disorders, as well as apple-based cosmetic products. All Yuhan products are manufactured according to strict quality standards and are known for their effectiveness and safety. Conclusion: The Yuhan Corporation has evolved into a diverse and innovative company focused on the production of drugs and health products. The company has a long history with many successes and has established itself as one of the major forces in the South Korean economy over the past decades. Yuhan's mission to create better healthcare remains as relevant today as it was at the time of its founding. Yuhan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yuhan stock

EBIT per Employee of Yuhan is 144.23 M KRW in 2025.

EBIT per Employee of Yuhan changed from 42.40 M KRW to 144.23 M KRW, representing a 240.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Yuhan since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Yuhan historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Yuhan

All Key Metrics — Yuhan